Locations:
SearchResults of multicenter trial led by Alok Khorana, M.D., presented as a late-breaking abstract at ASH 2018
Cleveland Clinic News Service | 216.444.0141
We’re available to shoot custom interviews & b-roll for media outlets upon request.
CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.
images: 0
video: 0
audio: 0
text: 0
SAN DIEGO: Cleveland Clinic medical oncologist and researcher, Alok Khorana, M.D., is the primary investigator on a study that concluded rivaroxaban for venous thromboembolism (VTE), a blood clot in the venous system, significantly reduced VTE and VTE-related death for outpatient, at-risk cancer patients while they were taking the oral blood thinner.
During the on-treatment period, blood clots occurred less frequently (2.62 percent) in patients taking rivaroxaban, compared to and 6.41 percent of the placebo groups. However, during the full study period – which included 180-day observation after the medication was stopped – the gap narrowed with blood clots occurring in 5.95 percent of patients in the rivaroxaban group, compared to 8.79 percent of the placebo groups.
Those taking rivaroxaban were less likely to die – 23.1 percent, compared to 29.5 percent in the placebo group for the combined endpoint of all-cause death and VTE. Major bleeding, a dangerous side effect of anticoagulants, occurred in less than 2 percent of patients – on par with what would be expected with prophylactic anticoagulation in cancer patients.
https://newsroom.clevelandclinic.org/wp-content/uploads/sites/4/2018/12/CANCER-BLOOD-CLOT.mp4
“These results tell us that rivaroxaban effectively prevents blood clots in at-risk cancer patients during the treatment period,” said Dr. Khorana. “Post-treatment, risk of VTE persists, with one-third of VTE or VTE-related death occurring in patients after rivaroxaban was discontinued.”
Dr. Khorana reports honoraria from Janssen and Bayer, both of which funded the study. This is the first time extended outpatient interventions to prevent blood clots in an at-risk cancer patient population has been tested with direct oral anticoagulants. Results were presented at the American Society of Hematology (ASH) Annual Meeting.
Blood clots are the second leading cause of death for cancer patients after cancer itself. One in five cancer patients will get a blood clot at some point during the natural history of their illness.
“Cancer patients can have complications – such as blood clots – from cancer itself, or from cancer treatment,” said Dr. Khorana. “These complications are distressing for patients, may delay treatment, and contribute to emergency room visits and hospitalizations which impact healthcare utilization and costs.”
Often cancer patients are administered blood thinners to prevent blood clots in the hospital setting, however, because cancer treatment is typically an outpatient procedure, most cancer-related blood clots occur out of the hospital. Current options for outpatients at risk for blood clots, studied by previous clinical trials, are low-molecular-weight heparins, which are injections that the patient must administer daily.
A patient’s risk of blood clots was identified at the time of chemotherapy initiation by the Khorana Score, designed by Dr. Khorana. The score predicts blood clots based on a collection of simple variables – type of cancer, body mass index and complete blood count (platelet, leukocyte, hemoglobin). Cancer patients with a Khorana score of 2 or greater are considered at higher risk for developing blood clots, and were included in the trial.
The primary endpoint in the double-blind, randomized, placebo-controlled, parallel-group, multicenter study was VTE or VTE-related death. Patients were randomized 1:1 to rivaroxaban 10 mg once daily or placebo for 180 days, and were checked for clots at the onset of the trial.
“This signals a change in the prevention approaches to cancer-associated VTE,” says Dr. Khorana. “We are moving into a new era of direct oral anticoagulants.”
Study results should inform future recommendations regarding the prevention of blood clots in at-risk ambulatory cancer patients.
Research was funded by Janssen and Bayer. Dr. Khorana reports honoraria from Janssen, Bayer, Pfizer, Halozyme, AngioDynamics, Trio Health and Seattle Genetics.
Editor’s Note: Cleveland Clinic cancer researchers are investigators on more than 100 abstracts being presented at the ASH 2018 annual meeting.
About Cleveland Clinic Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 52,000 employees are more than 3,600 full-time salaried physicians and researchers and 14,000 nurses, representing 140 medical specialties and subspecialties. Cleveland Clinic’s health system includes a 165-acre main campus near downtown Cleveland, 11 regional hospitals, more than 150 northern Ohio outpatient locations – including 18 full-service family health centers and three health and wellness centers – and locations in Weston, Fla.; Las Vegas, Nev.; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2017, there were 7.6 million outpatient visits, 229,000 hospital admissions and 207,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.
